Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma

• Status: Recruiting
• Trial end date: 2022-03-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of ARO-HIF2 injection (also referred to as ARO-HIF2) and to determine the recommended Phase 2 dose in the treatment of patients with advanced clear cell renal cell carcinoma (ccRCC).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Arrowhead Pharmaceuticals

Criteria

Inclusion Criteria:

• Women of childbearing potential must have a negative pregnancy test, cannot be breastfeeding and must be willing to use contraception

• Willing to provide written informed consent and to comply with study requirements

• Histologically confirmed locally advanced or metastatic clear cell renal cell carcinoma that has progressed during or after at least two prior therapeutic regimens which must include vascular endothelial growth factor (VEGF)-targeted therapy and checkpoint inhibitor therapy or that has otherwise failed such therapies, is measurable disease per RECIST 1.1 criteria, is biopsy accessible

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1

• Estimated life expectancy of longer than 3 months

• Adequate organ function at screening

Exclusion Criteria:

• History of untreated brain metastasis or leptomeningeal disease or spinal cord compression

• Failure to recover from reversible effects of prior anti-cancer therapy

• Has received systemic therapy or radiation therapy within 2 weeks prior to first dose

• History of solid organ or stem cell transplantation

• Current use of anti-VEGF or mammalian target of rapamycin (mTOR) agents, or chronic immunosuppressive therapy

• Any prior use of hypoxia inducible factor 2 (HIF2) inhibitors within 6 months prior to first dose

• Current use of immune checkpoint inhibitors

• Use of an investigational agent or device within 2 weeks prior to dosing, or current participation in an investigational study

• Known HIV, hepatitis B or hepatitis C

• History of other clinically meaningful disease

• Major surgery within 4 weeks of Screening

• Active malignancy requiring therapy other than ccRCC within 3 years of study entry

Note: Other eligibility criteria may apply per protocol.